Literature DB >> 6095731

Galactose neuropathy: impact of chronic endoneurial edema on nerve blood flow.

R R Myers, H C Powell.   

Abstract

Peripheral neuropathy induced by galactose feeding results in endoneurial edema with increased tissue pressure and ultimate demyelination of nerve fibers. To assess the role of ischemia in the pathogenesis of this neuropathy, nerve blood flow was measured 6 months after the start of galactose ingestion, between the onset of edema and nerve fiber changes. Measurement was carried out by a noninvasive technique involving the use of [14C]iodoantipyrine as a radioactive tracer of tissue perfusion. A significant decline in nerve blood flow was found, which correlated positively with increased nerve water content as quantified by a microgravimetric technique. We sought to establish the pathogenic role of nerve edema in the development of schwannopathy and demyelination by morphological examination. It was found that Schwann cells appeared normal in areas of the peripheral nervous system in which edema does not occur, such as spinal ganglia and roots, whereas in regions in which there was edema, massive glycogen accumulation in Schwann cells and demyelination occurred. These findings suggest that edema, rather than hyperactivity in the sorbitol pathway, is responsible for the pathological changes in galactosemic neuropathy and that ischemia resulting from edema and increased endoneurial fluid pressure is the mechanism responsible for fiber injury.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6095731     DOI: 10.1002/ana.410160510

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  14 in total

Review 1.  Diabetic peripheral neuropathy: should a chaperone accompany our therapeutic approach?

Authors:  Kevin L Farmer; Chengyuan Li; Rick T Dobrowsky
Journal:  Pharmacol Rev       Date:  2012-08-10       Impact factor: 25.468

2.  Effects of nerve compression on fast axonal transport in streptozotocin-induced diabetes mellitus. An experimental study in the sciatic nerve of rats.

Authors:  L B Dahlin; K F Meiri; W G McLean; B Rydevik; J Sjöstrand
Journal:  Diabetologia       Date:  1986-03       Impact factor: 10.122

3.  Treatment with an aldose reductase inhibitor can reduce the susceptibility of fast axonal transport following nerve compression in the streptozotocin-diabetic rat.

Authors:  L B Dahlin; D R Archer; W G McLean
Journal:  Diabetologia       Date:  1987-06       Impact factor: 10.122

4.  Pressure-induced inhibition of fast axonal transport of proteins in the rabbit vagus nerve in galactose neuropathy: prevention by an aldose reductase inhibitor.

Authors:  W G McLean
Journal:  Diabetologia       Date:  1988-07       Impact factor: 10.122

5.  Impaired sensory nerve function and axon morphology in mice with diabetic neuropathy.

Authors:  Richard C Lennertz; Karen A Medler; James L Bain; Douglas E Wright; Cheryl L Stucky
Journal:  J Neurophysiol       Date:  2011-06-08       Impact factor: 2.714

6.  Perivascular demyelination and intramyelinic oedema in reperfusion nerve injury.

Authors:  H Nukada; P D McMorran
Journal:  J Anat       Date:  1994-10       Impact factor: 2.610

7.  Response of the axon and barrier endothelium to experimental allergic neuritis induced by autoreactive T cell lines.

Authors:  H C Powell; R R Myers; A P Mizisin; T Olee; S W Brostoff
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

8.  Laser injury of peripheral nerve: a model for focal endoneurial damage.

Authors:  R R Myers; H E James; H C Powell
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-12       Impact factor: 10.154

9.  Dissociation between biochemical and functional effects of the aldose reductase inhibitor, ponalrestat, on peripheral nerve in diabetic rats.

Authors:  N E Cameron; M A Cotter
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

10.  Microangiopathy in human diabetic neuropathy.

Authors:  H C Powell; J Rosoff; R R Myers
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.